![](/img/cover-not-exists.png)
A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States
Stillman, I.O., Ambavane, A., Cislo, P.Volume:
16
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2013.08.500
Date:
November, 2013
File:
PDF, 61 KB
english, 2013